title: Supramolecular Cocrystals of Gliclazide: Synthesis, Characterization and Evaluation.
abstract: To prepare the supramolecular cocrystals of gliclazide (GL, a BCS class II drug molecule) via mechanochemical route, with the goal of improving physicochemical and biopharmaceutical properties.
  
  
  
  Two cocrystals of GL with GRAS status coformers, sebacic acid (GL-SB; 1:1) and α-hydroxyacetic acid (GL-HA; 1:1) were screened out using liquid assisted grinding. The prepared cocrystals were characterized using thermal and analytical techniques followed by evaluation of antidiabetic activity and pharmacokinetic parameters.
  
  
  
  The generation of new, single and pure crystal forms was characterized by DSC and PXRD. The crystal structure determination from PXRD revealed the existence of both cocrystals in triclinic (P-1) crystal system. The hydrogen bonded network, determined by material studio was well supported by shifts in FTIR and SSNMR. Both the new solid forms displayed improved solubility, IDR, antidiabetic activity and pharmacokinetic parameters as compared to GL.
  
  
  
  The improvement in these physicochemical and biopharmaceutical properties corroborated the fact that the supramolecular cocrystallization may be useful in the development of pharmaceutical crystalline materials with interesting network and properties.
authors.affiliation: University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India. renukchadha@rediffmail.com.
authors.forename: Renu
authors.initials: R
authors.lastname: Chadha
authors.affiliation: University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India.
authors.forename: Dimpy
authors.initials: D
authors.lastname: Rani
authors.affiliation: University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India.
authors.forename: Parnika
authors.initials: P
authors.lastname: Goyal
mesh_terms: D000818:Animals; D002626:Chemistry, Pharmaceutical; D003460:Crystallization; D003652:Decanoic Acids / Q000737:chemistry* / Q000493:pharmacokinetics; D003998:Dicarboxylic Acids / Q000737:chemistry* / Q000493:pharmacokinetics; D005907:Gliclazide / Q000737:chemistry* / Q000493:pharmacokinetics; D006016:Glycolates / Q000737:chemistry* / Q000493:pharmacokinetics; D006801:Humans; D006860:Hydrogen Bonding; D007004:Hypoglycemic Agents / Q000737:chemistry* / Q000493:pharmacokinetics; D008297:Male; D033362:Powder Diffraction; D051381:Rats; D017208:Rats, Wistar; D012995:Solubility; D017550:Spectroscopy, Fourier Transform Infrared; D014961:X-Ray Diffraction
chemical_list: D003652:Decanoic Acids; D003998:Dicarboxylic Acids; D006016:Glycolates; D007004:Hypoglycemic Agents; C031149:glycolic acid; C011107:sebacic acid; D005907:Gliclazide
keywords: biopharmaceutical; cocrystals; crystal structure; gliclazide; physicochemical